American Thoracic Society; American College of Chest Physicians ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2003 Jan 15;167(2):211-77. doi: 10.1164/rccm.167.2.211. No abstract available. Erratum In: Am J Respir Crit Care Med. 2003 May 15;1451-2.
Andrassy KM Comments on 'KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease'. Kidney Int. 2013 Sep;84(3):622-3. doi: 10.1038/ki.2013.243. No abstract available.
Bernheim J, Benchetrit S The potential roles of FGF23 and Klotho in the prognosis of renal and cardiovascular diseases. Nephrol Dial Transplant. 2011 Aug;26(8):2433-8. doi: 10.1093/ndt/gfr208. Epub 2011 May 4.
Bleyer AJ, Russell GB, Satko SG Sudden and cardiac death rates in hemodialysis patients. Kidney Int. 1999 Apr;55(4):1553-9. doi: 10.1046/j.1523-1755.1999.00391.x.
Boutou AK, Pitsiou GG, Argyropoulou P Non-invasive markers of pulmonary hypertension in interstitial lung disease: is cardiopulmonary exercise testing the Holy Grail? Respirology. 2014 Jul;19(5):621-2. doi: 10.1111/resp.12321. Epub 2014 May 15. No abstract available.
Carlisle J, Swart M Mid-term survival after abdominal aortic aneurysm surgery predicted by cardiopulmonary exercise testing. Br J Surg. 2007 Aug;94(8):966-9. doi: 10.1002/bjs.5734.
Cerasola G, Nardi E, Palermo A, Mule G, Cottone S Epidemiology and pathophysiology of left ventricular abnormalities in chronic kidney disease: a review. J Nephrol. 2011 Jan-Feb;24(1):1-10. doi: 10.5301/jn.2010.2030.
Ferrazza AM, Martolini D, Valli G, Palange P Cardiopulmonary exercise testing in the functional and prognostic evaluation of patients with pulmonary diseases. Respiration. 2009;77(1):3-17. doi: 10.1159/000186694. Epub 2009 Jan 14.
Foley RN, Gilbertson DT, Murray T, Collins AJ Long interdialytic interval and mortality among patients receiving hemodialysis. N Engl J Med. 2011 Sep 22;365(12):1099-107. doi: 10.1056/NEJMoa1103313.
Foley RN, Parfrey PS, Sarnak MJ Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998 Nov;32(5 Suppl 3):S112-9. doi: 10.1053/ajkd.1998.v32.pm9820470. No abstract available.
Georgianos PI, Sarafidis PA, Sinha AD, Agarwal R Adverse effects of conventional thrice-weekly hemodialysis: is it time to avoid 3-day interdialytic intervals? Am J Nephrol. 2015;41(4-5):400-8. doi: 10.1159/000435842. Epub 2015 Jun 27.
Georgianos PI, Sarafidis PA Pro: Should we move to more frequent haemodialysis schedules? Nephrol Dial Transplant. 2015 Jan;30(1):18-22. doi: 10.1093/ndt/gfu381. Epub 2014 Dec 23.
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004 Sep 23;351(13):1296-305. doi: 10.1056/NEJMoa041031. Erratum In: N Engl J Med. 2008;18(4):4.
Heiwe S, Clyne N, Dahlgren MA Living with chronic renal failure: patients' experiences of their physical and functional capacity. Physiother Res Int. 2003;8(4):167-77. doi: 10.1002/pri.287.
Heiwe S, Jacobson SH Exercise training for adults with chronic kidney disease. Cochrane Database Syst Rev. 2011 Oct 5;2011(10):CD003236. doi: 10.1002/14651858.CD003236.pub2.
London GM, Drueke TB Atherosclerosis and arteriosclerosis in chronic renal failure. Kidney Int. 1997 Jun;51(6):1678-95. doi: 10.1038/ki.1997.233. No abstract available.
National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266. No abstract available.
Older P, Hall A, Hader R Cardiopulmonary exercise testing as a screening test for perioperative management of major surgery in the elderly. Chest. 1999 Aug;116(2):355-62. doi: 10.1378/chest.116.2.355.
Older P, Smith R, Courtney P, Hone R Preoperative evaluation of cardiac failure and ischemia in elderly patients by cardiopulmonary exercise testing. Chest. 1993 Sep;104(3):701-4. doi: 10.1378/chest.104.3.701.
Pun PH The interplay between CKD, sudden cardiac death, and ventricular arrhythmias. Adv Chronic Kidney Dis. 2014 Nov;21(6):480-8. doi: 10.1053/j.ackd.2014.06.007. Epub 2014 Oct 24.
Sarafidis PA, Bakris GL Cardiovascular disease in CKD in 2014: new insights into cardiovascular risk factors and outcomes. Nat Rev Nephrol. 2015 Feb;11(2):70-2. doi: 10.1038/nrneph.2014.242. Epub 2014 Dec 16.
Segall L, Nistor I, Covic A Heart failure in patients with chronic kidney disease: a systematic integrative review. Biomed Res Int. 2014;2014:937398. doi: 10.1155/2014/937398. Epub 2014 May 15.
Sietsema KE, Amato A, Adler SG, Brass EP Exercise capacity as a predictor of survival among ambulatory patients with end-stage renal disease. Kidney Int. 2004 Feb;65(2):719-24. doi: 10.1111/j.1523-1755.2004.00411.x.
Wasserman K, Hansen JE, Sue DY, et al Principles of exercise testing and interpretation: including pathophysiology and clinical applications. Philadelphia (PA): Lipincott, Williams and Wilkins; 2005.
Wolf M Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol. 2010 Sep;21(9):1427-35. doi: 10.1681/ASN.2009121293. Epub 2010 May 27.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.